Cargando…

Dabigatran: Clinical correlation of drug and its dose with risk of stroke and bleeding

BACKGROUND: Dabigatran is the first oral direct thrombin inhibitor which is endorsed by Food and Drug Administration in the prevention of embolic events in patients with nonvalvular atrial fibrillation. Suitable dose of the drug for the patient is selected based on CHA2DS2-VASc score and HAS-BLED sc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shaji, Anitta, Thomas, Doody, Saju, Midhuna, Abraham, Suja, Nayak, Ramdas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003582/ https://www.ncbi.nlm.nih.gov/pubmed/36909213 http://dx.doi.org/10.4103/picr.picr_171_21

Ejemplares similares

Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study
por: Abraham, Neena S, et al.
Publicado: (2015)

Management of dabigatran-induced bleeding: expert statement
por: Fries, Dietmar, et al.
Publicado: (2013)

Risk of Ischemic Stroke, Hemorrhagic Stroke, Bleeding, and Death in Patients Switching from Vitamin K Antagonist to Dabigatran after an Ablation
por: Pallisgaard, Jannik Langtved, et al.
Publicado: (2016)

Risk factors and prevention of dabigatran‐related gastrointestinal bleeding in patients with atrial fibrillation
por: Nantsupawat, Teerapat, et al.
Publicado: (2017)

Major bleeding events in octagenarians associated with drug interactions between dabigatran and P-gp inhibitors
por: Bernier, Marjorie, et al.
Publicado: (2019)

Use of a specific antidote to dabigatran (idarucizumab) reduces blood loss and mortality in dabigatran-induced and trauma-induced bleeding in pigs
por: Honickel, M, et al.
Publicado: (2014)

Length of hospitalization and mortality for bleeding during treatment with warfarin, dabigatran, or rivaroxaban
por: Charlton, Blake, et al.
Publicado: (2018)

Dabigatran Plasma Measurement to Guide the Management of Acute Bleeding and Thrombotic Complications
por: Tala, Maurizio, et al.
Publicado: (2018)

Risk of Gastrointestinal Bleeding Among Dabigatran Users – A Self Controlled Case Series Analysis
por: Tang, Wenze, et al.
Publicado: (2017)

Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2017)

The Renal Elimination Pathways of the Dabigatran Reversal Agent Idarucizumab and its Impact on Dabigatran Elimination
por: Glund, Stephan, et al.
Publicado: (2018)

Safety and timing of resuming dabigatran after major gastrointestinal bleeding reversed by idarucizumab
por: Riario Sforza, Gian Galeazzo, et al.
Publicado: (2018)

Evaluation of the Bleeding Intensity of Patients Anticoagulated with Warfarin or Dabigatran Undergoing Dental Procedures
por: Andrade, Marcus Vinicius Santos, et al.
Publicado: (2018)

Real‐world use of idarucizumab for dabigatran reversal in three cases of serious bleeding
por: Gendron, Nicolas, et al.
Publicado: (2017)

Patient Characteristics and Clinical Outcomes with Low-Dose Dabigatran
por: Ebrahimi, Ramin, et al.
Publicado: (2017)

Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran
por: Glund, Stephan, et al.
Publicado: (2019)

Dabigatran Acylglucuronide, the Major Metabolite of Dabigatran, Shows a Weaker Anticoagulant Effect than Dabigatran
por: Kim, Jong-Min, et al.
Publicado: (2022)

Association Between the Change in Total Bilirubin and Risk of Bleeding Among Patients With Nonvalvular Atrial Fibrillation Taking Dabigatran
por: Xiong, Yurong, et al.
Publicado: (2020)

Design and development of an inflatable latex balloon to reduce rectal and bladder doses for patients undergoing high dose rate brachytherapy
por: Raghukumar, P., et al.
Publicado: (2009)

Re-initiation of dabigatran and direct factor Xa antagonists after a major bleed(,,)
por: Milling, Truman J., et al.
Publicado: (2016)

Re-Initiation of Dabigatran and Direct Factor Xa Antagonists After a Major Bleed
por: Milling, Truman J., et al.
Publicado: (2016)

Idarucizumab reverses dabigatran-induced anticoagulation in treatment of gastric bleeding: A case report
por: Jia, Yu, et al.
Publicado: (2022)

Dabigatran in Secondary Stroke Prevention: Clinical Experience with 106 Patients
por: DeFelipe-Mimbrera, Alicia, et al.
Publicado: (2014)

Concerns Regarding the Use of Dabigatran for Stroke Prevention in Atrial Fibrillation
por: Stöllberger, Claudia, et al.
Publicado: (2012)

Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation
por: Huber, K, et al.
Publicado: (2013)

The Dabigatran debate
por: Kaba, Riyaz A, et al.
Publicado: (2014)

Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban
por: Tepper, Ping G., et al.
Publicado: (2018)

No Influence of Dabigatran Anticoagulation on Hemorrhagic Transformation in an Experimental Model of Ischemic Stroke
por: Bohmann, Ferdinand, et al.
Publicado: (2012)

The clinical efficacy of dabigatran etexilate for preventing stroke in atrial fibrillation patients
por: Ellis, Christopher R, et al.
Publicado: (2013)

Burden of upper gastrointestinal symptoms in patients prescribed dabigatran for stroke prevention
por: Chan, Pak-Hei, et al.
Publicado: (2016)

Peripheral leukocyte count and risk of bleeding in patients with non-valvular atrial fibrillation taking dabigatran: a real-world study
por: Zhou, Wei, et al.
Publicado: (2019)

All-Cause, Stroke-, and Bleed-Specific Healthcare Costs: Comparison among Patients with Non-Valvular Atrial Fibrillation (NVAF) Newly Treated with Dabigatran or Warfarin
por: Gilligan, Adrienne M., et al.
Publicado: (2017)

The Discovery of Dabigatran Etexilate
por: van Ryn, Joanne, et al.
Publicado: (2013)

Dabigatran and apolipoprotein B
por: ten Cate, Hugo
Publicado: (2016)

Retrospective cohort study of the efficacy and safety of dabigatran: real-life dabigatran use including very low-dose 75 mg twice daily administration
por: Akagi, Yuuki, et al.
Publicado: (2019)

Determinants for a low dose of alteplase and its relationship to a lower intracerebral bleeding risk in acute ischemic stroke
por: Chen, Jie, et al.
Publicado: (2022)

Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
por: Wisløff, Torbjørn, et al.
Publicado: (2014)

Dabigatran Effect on Left Ventricular Thrombus in a Patient with Acute Ischemic Stroke
por: Chung, Kyuyoon, et al.
Publicado: (2015)

Immediate Reversal of Dabigatran by Idarucizumab Prior to Laboratory and Imaging Results in Acute Stroke
por: Hieber, Maren, et al.
Publicado: (2019)

Effects of dabigatran and rivaroxaban on stroke severity according to the results of routine coagulation tests
por: Cho, Han-Jin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fujchbv3h4sl5psgpk6j5i3nh6